Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19 DOI Creative Commons
Carolina do Prado Servian, Mônica Spadafora-Ferreira, Déborah Carolina Carvalho dos Anjos

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 9, 2023

Introduction Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces rapid production of IgM, IgA, and IgG antibodies directed to multiple viral antigens that may have impact diverse clinical outcomes. Methods We evaluated the nucleocapsid (NP), IgA Spike protein receptor-binding domain (RBD), presence neutralizing (nAb), in a cohort unvaccinated SARS-CoV-2 infected individuals, first 30 days post-symptom onset (PSO) (T1). Results This study included 193 disease 2019 (COVID-19) participants classified as mild, moderate, severe, critical, fatal 27 uninfected controls. In T1, we identified differential antibody profiles associated with distinct presentation. The mild group presented lower levels anti-NP IgG, (vs moderate severe), IgM critical fatal), anti-Spike anti-RBD severe). higher comparing group. fatal) moderate). mild), but nAb was just compared groups, moreover, no difference observed among more groups. addition, studied 82 convalescent between 31 6 months (T2) or than (T3), PSO, those: 12 26 46 plus critical. longitudinal analyzes, for showed relation T3. follow-up group, reveals anti-spike increased, while decreased along time severe/critical well several/critical Discussion summary, survival individuals admitted intensive care unit (ICU). Collectively, our data discriminate death from survival, suggesting play some deleterious effect, contrast potentially protective effect

Language: Английский

Development and evaluation of a Lateral flow immunoassay (LFIA) prototype for the detection of IgG anti-SARS-CoV-2 antibodies DOI Creative Commons
Matheus Bernardes Torres Fogaça, Djairo Pastor Saavedra, Leonardo Lopes-Luz

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(9), P. e29938 - e29938

Published: April 18, 2024

Lateral flow immunoassays (LFIA) for antibody detection represent cost-effective and user-friendly tools serology assessment. This study evaluated a new LFIA prototype developed with recombinant chimeric antigen from the spike/S nucleocapsid/N proteins to detect anti-SARS-CoV-2 IgG antibodies. The evaluation of sensitivity specificity used 811 serum samples 349 hospitalized, SARS-CoV-2 RT-qPCR positive COVID-19 patients, collected at different time points 193 healthy controls. agreement between ELISA results S/N was calculated. using protein demonstrated 85% on first week post symptoms onset, reaching 94% in fourth disease. same 92.7%, 0.827 kappa Cohen value (95% CI [0.765 – 0.889]). Further improvements are needed standardize whole blood use. inclusion novel S+N optimal comparable ELISA, highlighting prototype's potential accurate large-scale serologic assessments field rapid format.

Language: Английский

Citations

1
Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19 DOI Creative Commons
Carolina do Prado Servian, Mônica Spadafora-Ferreira, Déborah Carolina Carvalho dos Anjos

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 9, 2023

Introduction Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces rapid production of IgM, IgA, and IgG antibodies directed to multiple viral antigens that may have impact diverse clinical outcomes. Methods We evaluated the nucleocapsid (NP), IgA Spike protein receptor-binding domain (RBD), presence neutralizing (nAb), in a cohort unvaccinated SARS-CoV-2 infected individuals, first 30 days post-symptom onset (PSO) (T1). Results This study included 193 disease 2019 (COVID-19) participants classified as mild, moderate, severe, critical, fatal 27 uninfected controls. In T1, we identified differential antibody profiles associated with distinct presentation. The mild group presented lower levels anti-NP IgG, (vs moderate severe), IgM critical fatal), anti-Spike anti-RBD severe). higher comparing group. fatal) moderate). mild), but nAb was just compared groups, moreover, no difference observed among more groups. addition, studied 82 convalescent between 31 6 months (T2) or than (T3), PSO, those: 12 26 46 plus critical. longitudinal analyzes, for showed relation T3. follow-up group, reveals anti-spike increased, while decreased along time severe/critical well several/critical Discussion summary, survival individuals admitted intensive care unit (ICU). Collectively, our data discriminate death from survival, suggesting play some deleterious effect, contrast potentially protective effect

Language: Английский

Citations

3